DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
The generic ingredient in XENLETA is lefamulin acetate. One supplier is listed for this compound. Additional details are available on the lefamulin acetate profile page.
Generic Entry Opportunity Date for 211672
Generic Entry Date for 211672*:
Constraining patent/regulatory exclusivity:
GENERATING ANTIBIOTIC INCENTIVES NOW
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Profile for product number 001
|Active Rx/OTC/Discontinued:||RX||Dosage:||TABLET;ORAL||Strength||EQ 600MG BASE|
|Approval Date:||Aug 19, 2019||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||Aug 19, 2029|
|Regulatory Exclusivity Use:||GENERATING ANTIBIOTIC INCENTIVES NOW|
|Regulatory Exclusivity Expiration:||Aug 19, 2024|
|Regulatory Exclusivity Use:||NEW CHEMICAL ENTITY|
Complete Access Available with Subscription